[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"blindness\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:blindness":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,9,0,[8,60,132,156,190,215,238,273,302],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":37,"overallStatus":47,"whyStopped":4,"lastUpdateSubmitDate":48,"lastUpdatePostDateStruct":49,"startDateStruct":52,"completionDateStruct":54,"leadSponsor":56,"locationsCount":59},"100584599","phase-3-study-to-evaluate-sepofarsen-in-subjects-with-leber-congenital-amaurosis-lca-type-10-hyperion-100584599",false,"NCT06891443","Study to Evaluate Sepofarsen in Subjects With Leber Congenital Amaurosis (LCA) Type 10 (HYPERION)","A Double-Masked, Randomized, Placebo-Controlled, Paired-Eye Study to Evaluate the Efficacy, Safety and Tolerability of Sepofarsen in Subjects With Leber Congenital Amaurosis (LCA) Due to the c.2991+1655A>G (p.Cys998X) Mutation in the CEP290 Gene","HYPERION","Inclusion Criteria:\n\n1. Confirmed clinical diagnosis of LCA10 and a molecular diagnosis of homozygosity or compound heterozygosity for the c.2991+1655A\\>G mutation in CEP290.\n2. Adults: \\>=18 years \u002F Minors: 6 to \\\u003C18 years.\n3. BCVA (FrACT) equal to or worse than logMAR +0.4 (approximate Snellen equivalent 20\u002F50) to +2.9 logMAR based on quantifiable, reliable FrACT. LP subjects with documented evidence of prior better vision eligible.\n4. Symmetrical disease between the two eyes as defined by a BCVA (FrACT) within 0.2 logMAR at baseline.\n5. Detectable ONL in the macular area as determined by the CRC at Screening.\n\nExclusion Criteria:\n\n1. Mutations in genes other than the CEP290 gene associated with other IRD diseases or syndromes.\n2. Presence of any ocular pathology in either eye that may make comparison of the eyes not feasible.\n3. Presence of unstable concurrent CME, or subject started on (or changed dose of) topical or systemic carbonic anhydrase inhibitor treatment in the 3 months prior to enrollment. CME is allowed if stable for 3 months (with or without treatment).\n4. Presence of any clinically significant lens opacities\u002Fcataracts based on the AREDS lens grading scale.\n5. Any prior receipt of genetic (RNA or DNA therapy) or stem-cell therapy for ocular or non-ocular disease, including sepofarsen.","ALL","6 Years",{"count":20,"type":21},32,"ESTIMATED","INTERVENTIONAL",[24],"PHASE3","The purpose of this double-masked, randomized, placebo-controlled, paired-eye study is to evaluate the efficacy, safety and tolerability of Sepofarsen in subjects with Leber Congenital Amaurosis (LCA) due to the c.2991+1655A\\>G (p.Cys998X) mutation in the CEP290.",[27,28,29,30,31,32,33,34,35,36],"Leber Congenital Amaurosis 10","Blindness","Leber Congenital Amaurosis","Sensation Disorders","Vision Disorder","Neurological Manifestations","Eye Diseases, Hereditary","Eye Diseases","Eye Disorders Congenital","Retinal Disease",[38,39,40,41,42,43,44,45,46],"LCA10","p.Cys998X","Antisense oligonucleotides","RNA therapy","QR-110","sepofarsen","CEP290","Leber's Congenital Amaurosis","c.2991+1655A>G","RECRUITING","2026-06-24",{"date":50,"type":51},"2026-06-25","ACTUAL",{"date":53,"type":51},"2025-06-04",{"date":55,"type":21},"2028-10",{"name":57,"class":58},"Laboratoires Thea","INDUSTRY",17,{"id":61,"slug":62,"hasResults":11,"nctId":63,"briefTitle":64,"officialTitle":65,"acronym":66,"eligibilityCriteria":67,"healthyVolunteers":11,"sex":17,"minAge":68,"maxAge":4,"enrollmentInfo":69,"targetDuration":4,"studyType":22,"phases":71,"briefSummary":73,"conditions":74,"keywords":91,"overallStatus":47,"whyStopped":4,"lastUpdateSubmitDate":48,"lastUpdatePostDateStruct":123,"startDateStruct":125,"completionDateStruct":127,"leadSponsor":129,"locationsCount":131},"100286660","stem-cell-ophthalmology-treatment-study-ii-100286660","NCT03011541","Stem Cell Ophthalmology Treatment Study II","Bone Marrow Derived Stem Cell Ophthalmology Treatment Study II","SCOTS2","Inclusion Criteria:\n\n* Have objective, documented damage to the retina or optic nerve unlikely to improve OR\n* Have objective, documented damage to the retina or optic nerve that is progressive AND have less than or equal to 20\u002F30 best corrected central visual acuity in one or both eyes AND\u002FOR an abnormal visual field in one or both eyes.\n* Be at least 3 months post-surgical treatment intended to treat any ophthalmologic disease and stable.\n* If under current medical therapy ( pharmacologic treatment) for a retinal or optic nerve disease be considered stable on that treatment and unlikely to have visual function improvement ( for example, glaucoma with intraocular pressure stable on topical medications but visual field damage ).\n* Have the potential for improvement with BMSC treatment and be at minimal risk of any potential harm from the procedure.\n* Be over the age of 18\n* Be medically stable and able to be medically cleared by their primary care physician or a licensed primary care practitioner for the procedure.\n* Medical clearance means that in the estimation of the primary care practitioner, the patient can reasonably be expected to undergo the procedure without significant medical risk to health.\n\nExclusion Criteria:\n\n* Patients who are not capable of an adequate ophthalmologic examination or evaluation to document the pathology.\n* Patients who are not capable or not willing to undergo follow up eye exams with the principle investigator or their ophthalmologist or optometrist as outlined in the protocol.\n* Patients who are not capable of providing informed consent.\n* Patients who may be at significant risk to general health or to the eyes and visual function should they undergo the procedure.","18 Years",{"count":70,"type":21},500,[72],"NA","This study will evaluate the use of autologous bone marrow derived stem cells (BMSC) for the treatment of retinal and optic nerve damage or disease.",[36,75,76,77,78,79,80,81,82,83,28,84,85,86,87,88,89,90],"Age-Related Macular Degeneration","Retinitis Pigmentosa","Stargardt Disease","Optic Neuropathy","Nonarteritic Ischemic Optic Neuropathy","Optic Atrophy","Optic Nerve Disease","Glaucoma","Leber Hereditary Optic Neuropathy","Vision Loss Night","Vision Loss Partial","Vision, Low","Retinopathy","Maculopathy","Macular Degeneration","Retina Atrophy",[92,93,94,95,96,97,98,99,100,36,89,101,102,103,104,105,106,107,108,109,76,77,110,111,112,88,81,80,78,113,114,115,116,117,118,119,120,121,83,28,122,90],"Stem Cells","Bone Marrow Derived Stem Cells","BMSC","Mesenchymal Stem Cells","MSC","Eye Disease","Ophthalmology","Ophthalmic Disease","Retina","Age Related Macular Degeneration","Myopic Macular Degeneration","Geographic Atrophy","Dry Macular Degeneration","Wet Macular Degeneration","Retinal Atrophy","Retinal Dystrophy","Hereditary Retinal Dystrophy","Malattia Leventinese","Cone Dystrophy","Rod-Cone Dystrophy","Cone-Rod Dystrophy","Ischemic Optic Neuropathy","Optic Nerve Damage","Optic Nerve Compression","Compressive Optic Neuropathy","Devics Syndrome","Ushers Syndrome","Neuromyelitis Optica","Dominant Optic Atrophy","Kjers Optic Atrophy","Vision Loss",{"date":124,"type":51},"2026-06-29",{"date":126,"type":51},"2016-01",{"date":128,"type":21},"2028-07-31",{"name":130,"class":58},"MD Stem Cells",4,{"id":133,"slug":134,"hasResults":11,"nctId":135,"briefTitle":136,"officialTitle":137,"acronym":138,"eligibilityCriteria":139,"healthyVolunteers":11,"sex":17,"minAge":68,"maxAge":140,"enrollmentInfo":141,"targetDuration":4,"studyType":22,"phases":143,"briefSummary":144,"conditions":145,"keywords":4,"overallStatus":47,"whyStopped":4,"lastUpdateSubmitDate":146,"lastUpdatePostDateStruct":147,"startDateStruct":149,"completionDateStruct":151,"leadSponsor":152,"locationsCount":155},"100284497","development-of-a-cortical-visual-neuroprosthesis-for-the-blind-100284497","NCT02983370","Development of a Cortical Visual Neuroprosthesis for the Blind","Pilot Study for the Development of a Cortical Visual Neuroprosthesis for the Blind Based on Intracortical Microelectrodes","CORTIVIS","Inclusion Criteria:\n\n* Participant is capable and willing to provide informed consent for participation in the trial.\n* Severe visual impairment with bilateral visual loss.\n* Greater than 18 years of age.\n* General health: excellent.\n* Following a general physical and neurological examination, patient must have normal serum electrolytes, C-reactive protein, complete blood count and PT and PTT.\n* No history of stroke, seizure, coagulopathy, cardiac arrhythmias or ischemia, pulmonary, hepatic or renal disease, nor transmissible viruses such as hepatitis or HIV.\n* Stable dose of current regular medication for at least four weeks prior to trial entry.\n* Able to perform the study during the full time period of up to 6 months.\n\nSpecial consideration will be given to patients with (1) detailed medical histories, including documentation of the onset, mechanism and evolution of the blindness; (2) lower risks associated with surgery; and (3) no psychiatric disorders or other mental disabilities.\n\nExclusion Criteria:\n\n* Age \\\u003C18 or \\>70.\n* Period of appropriate visual functions \\\u003C 12 years \u002Flifetime.\n* For medical reasons: Individuals with a history of seizure disorders, coagulopathy, cardiac arrythmias or ischemia, pulmonary, hepatic or renal disease, and any other neurological disorder. Patients who carry a transmissible virus such as hepatitis and individuals with HIV-related neuropathies.\n* Vulnerable subject groups (e.g., pregnant women, prisoners, etc.).\n* Persons unable to give written informed consent prior to participation in the study.\n* Not able to perform the study during the full time period (at least 3 months).\n* Any other significant disease or disorder which, in the opinion of the Investigator, may either put the participants at risk because of participation in the trial, or may influence the result of the trial, or the participant's ability to participate in the trial.","70 Years",{"count":142,"type":21},5,[72],"The objective of this study is to evaluate the usefulness of a cortical visual prosthesis based on intracortical microelectrodes to provide a limited but useful sense of vision to profoundly blind. This pilot study will provide important information on safety and efficacy for the development of an useful cortical visual neuroprosthesis for the blind.",[28],"2026-04-28",{"date":148,"type":51},"2026-05-05",{"date":150,"type":51},"2019-10-01",{"date":55,"type":21},{"name":153,"class":154},"Universidad Miguel Hernandez de Elche","OTHER",2,{"id":157,"slug":158,"hasResults":11,"nctId":159,"briefTitle":160,"officialTitle":161,"acronym":162,"eligibilityCriteria":163,"healthyVolunteers":164,"sex":17,"minAge":165,"maxAge":166,"enrollmentInfo":167,"targetDuration":4,"studyType":22,"phases":169,"briefSummary":170,"conditions":171,"keywords":172,"overallStatus":180,"whyStopped":4,"lastUpdateSubmitDate":181,"lastUpdatePostDateStruct":182,"startDateStruct":184,"completionDateStruct":186,"leadSponsor":188,"locationsCount":155},"100627595","sensory-substitution-and-brain-plasticity-following-vision-loss-100627595","NCT07450677","Sensory Substitution and Brain Plasticity Following Vision Loss","Neurobehavioral Effects of Visual Assistive Technologies","SenSubMRI","Inclusion Criteria:\n\n1. 8-85 years old for blind individuals; or 18-85 years old for sighted controls.\n2. (a) Blind due to ocular impairment (documented visual acuity of light perception or worse) in both eyes, or (b) sighted healthy adult controls with corrected visual acuity of 20\u002F40 or better and with no known vision disorders.\n3. Able to hear the Informed Consent Form being read out to him or her, to understand it, and sign the Informed Consent Form.\n4. Able to undergo functional neuroimaging tests.\n5. Able to walk and stand independently.\n6. Able to understand and remember the training protocols involved in the research study.\n7. Willing and able to use the provided sensory substitution system to solve simple visual tasks.\n8. Willing and able to complete simple tactile or auditory tasks.\n9. Able to communicate by telephone and\u002For computer with research staff.\n\nExclusion Criteria:\n\n1. Prior use with the sensory substitution device under investigation. This applies to both the auditory and tactile stimulators.\n2. Presence of any foreign metal in the body, except for dental fillings (will need to be pre-screened by a radiologist prior to signing the informed consent and enrollment).\n3. Pregnant or breastfeeding by self-report or urine test.\n4. Is a prisoner or has any required movements legally restricted.\n5. Unwilling or unable to adhere to all study requirements, including completion of the training period and any evaluation tests.\n6. Implanted electrical medical devices such as pacemakers.\n7. Claustrophobia that would prevent functional neuroimaging.\n8. Obesity preventing placement in the MRI scanner.\n9. No known neurological disorders or any medical condition that can possibly lead to emergency medical care (e.g., history of seizures, family history of epilepsy, stroke, severe headaches, use of medication for neurological or psychiatric conditions).\n10. Documented or suspected brain damage resulting in significant cognitive or sensory impairment (e.g., traumatic brain injury).",true,"8 Years","85 Years",{"count":168,"type":21},200,[72],"The goal of this clinical investigation is to learn how the brain responds when visual information is converted into patterns of sound or touch in blind and sighted participants. The main questions it aims to answer are:\n\n* Does converting visual information into sound or touch patterns change visual performance in the blind or blindfolded?\n* How does the brain adapt to different kinds of sensory information?\n\nResearchers will use brain imaging and simple performance tasks to see how people process and learn from this type of converted sensory input. The investigators will compare how individuals with and without long-term vision loss respond to these signals.\n\nParticipants will:\n\n* Learn to use technologies to assist in visual information conversion into sound or touch patterns every day for 5 weeks;\n* Visit the brain imaging center 3 times for brain scans and behavioral tests.",[28],[28,173,174,175,176,177,178,179],"Visual cortex","Sensory substitution","Assistive technology","Magnetic resonance imaging","Brain","Sound","Touch","NOT_YET_RECRUITING","2026-03-01",{"date":183,"type":51},"2026-03-05",{"date":185,"type":21},"2026-06-01",{"date":187,"type":21},"2030-08-31",{"name":189,"class":154},"Stanford University",{"id":191,"slug":192,"hasResults":11,"nctId":193,"briefTitle":194,"officialTitle":195,"acronym":4,"eligibilityCriteria":196,"healthyVolunteers":164,"sex":17,"minAge":197,"maxAge":4,"enrollmentInfo":198,"targetDuration":4,"studyType":22,"phases":200,"briefSummary":201,"conditions":202,"keywords":203,"overallStatus":180,"whyStopped":4,"lastUpdateSubmitDate":205,"lastUpdatePostDateStruct":206,"startDateStruct":208,"completionDateStruct":210,"leadSponsor":212,"locationsCount":214},"100557562","validation-of-texture-changing-coatings-for-use-in-at-home-rapid-tests-100557562","NCT06539728","Validation of Texture Changing Coatings for Use in At-Home Rapid Tests","Validation of Texture-Changing Tactile Coatings for Potential Use in Accessible At-Home Care","Inclusion Criteria:\n\n* Visual Impairment: Participants should be blind or visually impaired for greater than 10 years, either congenitally or acquired.\n* Tactile Aid Usage: Participants must use tactile aids regularly.\n* Mathematical Knowledge: Participants should have a basic understanding of mathematical plots, equivalent to at least high school geometry.\n\nExclusion Criteria:\n\n* Limb Conditions: Participants with amputations or outer extremity conditions affecting hand use will be excluded.","12 Years",{"count":199,"type":21},20,[72],"At-home testing is an important part of mitigating the spread of COVID-19, but these tests are not accessible to people with low vision or blindness. Instead of adapting to a technology originally built for sighted people, investigators propose a no-power version that reports test results through a texture change, which people can feel by touch. This platform could be used not only for COVID, but also for other diagnostics, and will promote the independence and privacy for people with low vision or blindness by removing the need for human assistance or an internet connection.",[86,28],[204],"Tactile Aid","2025-04-03",{"date":207,"type":51},"2025-04-06",{"date":209,"type":21},"2025-06",{"date":211,"type":21},"2025-08",{"name":213,"class":154},"University of Delaware",1,{"id":216,"slug":217,"hasResults":11,"nctId":218,"briefTitle":219,"officialTitle":219,"acronym":220,"eligibilityCriteria":221,"healthyVolunteers":164,"sex":17,"minAge":165,"maxAge":4,"enrollmentInfo":222,"targetDuration":4,"studyType":224,"phases":4,"briefSummary":225,"conditions":226,"keywords":4,"overallStatus":47,"whyStopped":4,"lastUpdateSubmitDate":229,"lastUpdatePostDateStruct":230,"startDateStruct":232,"completionDateStruct":234,"leadSponsor":236,"locationsCount":214},"100521505","holistic-mixed-approaches-to-capture-the-real-life-of-children-with-rare-eye-diseases-100521505","NCT06070467","Holistic Mixed Approaches to Capture the Real Life of Children With Rare Eye Diseases","SeeMyLife","Inclusion Criteria:\n\n* Children (age 8-12) and teenagers (age 13-18) with various levels of visual impairment defined according to World Health Organization (WHO) International Classification of Diseases (ICD) 10 - WHO ICD 10 \\[best-corrected visual acuity ≤ 0.3 decimal or ≤ 6\u002F18\\], and their parents\u002Fcaregivers.\n\nExclusion Criteria:\n\n* Children, teenagers, and caregivers:\n\n  1. who lack the ability to respond in a reliable way to the questions on how they feel about their visual impairment (patients with mild intellectual or cognitive deficiency may be able to reply accurately as opposed to cases with severe intellectual disability)\n  2. with functional or non-ophthalmic reasons of visual impairment\n  3. unable to provide consent\u002Fassent;\n  4. who do not speak\u002Fread the language",{"count":223,"type":21},154,"OBSERVATIONAL","Rare Eye Diseases (RED) are the leading cause of severe visual impairment\u002F blindness (SVI\u002FB) in children in Europe. This sensory disability with its accompanying psychological distress hugely impacts their lives and their families. Understanding this impact, at a patient centred level, is key in care, in shared decision making, in developing therapies, and in improving social integration and participation about the standard rules of the United Nations (UN) and the European Union (EU) (prevention, non-discrimination, equal opportunities, accessibility, etc.). However, current tools to evaluate vision related (VR) quality of life (QoL) VR-QoL disregard age and cultural differences. There is a lack knowledge on how the disease matters at child's level. Instruments capable of yielding high-quality data, psychometrically robust and comply with regulatory requirements remain to be developed.\n\nTo fill this gap, SeeMyLife will use multilevel concurrent mixed method research combining quantitative studies and qualitative studies. The quantitative approach is based on (i) cross culturally translated validated VR-QoL questionnaires for children and teenagers (Functional Vision Questionnaire for Children and Young People - FVQ-CYP and Vision-related Quality of Life Questionnaire for Children and Young People - VQoL-CYP) and (ii) on caregiver's questionnaires addressing participation and environment (Participation and Environment Measure - Children and Youth - PEM-CY). To fully capture the picture of the child\u002Fteenager personal life the investigators will reinforce their investigations by in depth qualitative socio-anthropologic study with semi directive field interviews and fieldwork (to observe closely the living conditions of the children) to address how their impairment affects their wellbeing, social integration, and how they feel about medical and social interventions. Data analysis will use an integrated mixed method strategy to validate the quantitative tools and deliver a holistic QoL transnational tool.\n\nThe SeeMyLife project will provide (i) robust patient self-reported tools that will be then used in care and research (especially with the rise in novel therapies) as a standard as well as (ii) highly awaited knowledge about the SVI\u002FB patient's position within his own life course, within his family and in relation to health and social care actors.",[34,227,28,228],"Severe Loss of Vision","Quality of Life","2024-08-27",{"date":231,"type":51},"2024-08-29",{"date":233,"type":51},"2024-07-17",{"date":235,"type":21},"2026-07",{"name":237,"class":154},"University Hospital, Strasbourg, France",{"id":239,"slug":240,"hasResults":11,"nctId":241,"briefTitle":242,"officialTitle":242,"acronym":243,"eligibilityCriteria":244,"healthyVolunteers":11,"sex":17,"minAge":68,"maxAge":4,"enrollmentInfo":245,"targetDuration":4,"studyType":224,"phases":4,"briefSummary":247,"conditions":248,"keywords":257,"overallStatus":47,"whyStopped":4,"lastUpdateSubmitDate":264,"lastUpdatePostDateStruct":265,"startDateStruct":267,"completionDateStruct":269,"leadSponsor":271,"locationsCount":214},"100554564","visual-involvement-in-giant-cell-arteritis-100554564","NCT06500728","Visual Involvement in Giant Cell Arteritis","Visu-GCA","Inclusion Criteria:\n\n* For GCA group:\n\n  * Patients older than 18 years with clinically suspected or confirmed gigantocellular arteritis.\n  * Newly found visual involvement with suspected or confirmed correlation with vasculitis.\n  * Ability to express valid consent to study enrolment.\n* For control group:\n\n  * Patients older than 18 years with the ability to express valid consent to study enrolment.\n  * Newly diagnosed acute visual impairment with GCA phenotypes (e.g. AION, CRAO) but without any correlation with vasculitis aetiology.\n\nExclusion Criteria:\n\n* Pre-existing ophthalmological pathologies that may modify best visual acuity and\u002For alter ophthalmological semeiotics.\n* Concomitant active viral, bacterial, fungal and parasitic infections, including active or latent tuberculosis treated for less than 4 weeks and HIV, hepatitis C virus (HCV)\n\n  \u002Fhepatitis B virus (HBV) infections, involving the eyes and orbital cavities.\n* Concomitant systemic inflammations not attributable to GCA (inflammatory diseases in treatment-free remission are not excluded).\n* Any other condition judged by the investigators to be a contraindication of eligibility",{"count":246,"type":21},762,"This observational study aims to enhance the description of the different ways Giant Cell Arteritis (GCA) affects vision. The latest technology and knowledge are used to improve how we diagnose and predict patient outcomes. GCA is the most frequent vasculitis, an inflammation of vessels, in older adults. It involves large and medium-sized arteries and causes ischemic alterations such as stroke and blindness, through damage of extracranial arteries.\n\nThe primary objective is to compare the frequency of the various ocular findings between the main alterations of arteritic and non-arteritic aetiology, such as Arteritic Anterior Ischemic Optic Neuropathy (A-AION) Vs. Non-Arteritic Anterior Ischemic Optic Neuropathy (NA-AION) or Central Retinal Artery Occlusion (CRAO) from GCA Vs. from other causes, through a comprehensive clinical and instrumental evaluation.",[249,250,251,252,253,254,255,28,256],"Giant Cell Arteritis","Visual Impairment","Central Retinal Artery Occlusion","Anterior Ischemic Optic Neuropathy","Paracentral Acute Middle Maculopathy","Posterior Ischemic Optic Neuropathy","Retinal Ischemia","Visual Disorder",[249,258,259,260,261,262,263],"Visual impairment","Optical Coherence Tomography (OCT)","High resolution Optical Coherence Tomography (HR-OCT)","Angio-Optical Coherence Tomography (OCT-A)","Fluorescein angiography","Indocyanine green angiography","2024-07-08",{"date":266,"type":51},"2024-07-15",{"date":268,"type":51},"2024-06-27",{"date":270,"type":21},"2030-06",{"name":272,"class":154},"ASST Fatebenefratelli Sacco",{"id":274,"slug":275,"hasResults":11,"nctId":276,"briefTitle":277,"officialTitle":277,"acronym":278,"eligibilityCriteria":279,"healthyVolunteers":11,"sex":17,"minAge":68,"maxAge":4,"enrollmentInfo":280,"targetDuration":4,"studyType":22,"phases":281,"briefSummary":283,"conditions":284,"keywords":292,"overallStatus":47,"whyStopped":4,"lastUpdateSubmitDate":293,"lastUpdatePostDateStruct":294,"startDateStruct":296,"completionDateStruct":298,"leadSponsor":300,"locationsCount":214},"100550753","early-phase-1-novel-antisense-oligonucleotide-eye-drops-for-treating-antibiotic-resistant-bacterial-keratitis-100550753","NCT06451172","Novel Antisense Oligonucleotide Eye Drops for Treating Antibiotic-Resistant Bacterial Keratitis","ASOTARI","Inclusion Criteria:\n\n* The results of antimicrobial susceptibility testing in patients with bacterial keratitis showed multidrug-resistant bacterial infections, and the existing commercial antibiotics could not effectively control the disease.\n* Age over 18 years.\n* No systemic immune eye disease.\n* Good eyelid structure and blink function.\n* Exists the potential of visual recovery by evaluation of ocular structure and function.\n* Subjects or their legal guardians voluntarily participate in this study, sign informed consent, good compliance and cooperation with follow-up visits.\n\nExclusion Criteria:\n\n* Lacrimal coating and blink function loss.\n* Schirmer's test result is less than 2mm for severe dry eye disease.\n* Pregnant and lactating women (pregnancy defined in this study as positive urine pregnancy test).\n* Currently is involved in clinical trials of other drugs or medical devices.\n* Active eye infection (including but not limited to: blepharitis, infectious conjunctivitis, sclerotitis, endophthalmitis) in target eye or contralateral eye within 30 days prior to enrollment.\n* Ocular surface malignant tumor.\n* A history of allergic reaction or allergy to sodium luciferin, allergy to protein products used for treatment or diagnosis, allergy to ≥ 2 drugs or non-drug factors, or current allergic disease.\n* current in an infectious disease requiring oral, intramuscular or intravenous administration.\n* Patients with systemic immune diseases.\n* Any uncontrolled clinical problems (such as severe mental, neurological, cardiovascular, respiratory and other systemic diseases and malignant neoplasms).\n* Not effective contraception.\n* In uncontrolled hypertension, systolic is no less than 160 mmhg, diastolic is no less than 100 mmhg.\n* In uncontrolled diabetes, fasting glucose is no less than 10.0umol\u002FL.\n* Renal insufficiency, serum creatinine is more than 133umol\u002FL.\n* Arrhythmia, myocardial ischemia, myocardial infarction (diagnosed by electrocardiogram).\n* Liver dysfunction, al ANINE aminotransferase and aspartate aminotransferase levels are higher than 80 IU\u002FL.\n* Platelet level is below 100,000 \u002FuL or above 450,000 \u002FuL.\n* Hemoglobin level is below 10.0g\u002FdL (male) or 9.0g\u002FdL (female).\n* No anticoagulant was used, prothrombin time is higher than 16s, and thrombin time of activated part is higher than 50s.\n* HIV infection (HIV-positive).\n* Subjects lack compliance with the study or the ability to sign informed consent.\n* There are currently signs of systemic infection, including fever and ongoing antibiotic treatment (in this study, systemic infection was defined as deviation from normal values of white blood cells, lymphocytes, and neutrophils on routine blood tests).\n* Administration of Glucocorticoids and other systemic immunosuppressive drugs.\n* The investigator judges other conditions unsuitable for the trial",{"count":199,"type":21},[282],"EARLY_PHASE1","The purpose of this study is to evaluate the safety and efficacy of GP-asPNA for in vivo treatment of severe antibiotic resistant bacterial keratitis.",[285,286,287,288,34,289,30,28,290,291],"Bacterial Keratitis","Antibiotic-resistant Bacteria","Infections, Bacterial","Corneal Diseases","Vision Disorders","Antisense Peptide Nucleic Acid","Antibacterial Therapy",[285,287,288,34],"2024-06-08",{"date":295,"type":51},"2024-06-11",{"date":297,"type":51},"2023-10-11",{"date":299,"type":21},"2026-10-31",{"name":301,"class":154},"Eye & ENT Hospital of Fudan University",{"id":303,"slug":304,"hasResults":11,"nctId":305,"briefTitle":306,"officialTitle":306,"acronym":4,"eligibilityCriteria":307,"healthyVolunteers":164,"sex":17,"minAge":308,"maxAge":4,"enrollmentInfo":309,"targetDuration":4,"studyType":22,"phases":311,"briefSummary":312,"conditions":313,"keywords":314,"overallStatus":47,"whyStopped":4,"lastUpdateSubmitDate":315,"lastUpdatePostDateStruct":316,"startDateStruct":318,"completionDateStruct":320,"leadSponsor":322,"locationsCount":214},"100534361","testing-tactile-aids-with-blind-subjects-100534361","NCT06237829","Testing Tactile Aids With Blind Subjects","Inclusion Criteria:\n\n* Visual Impairment: Participants should be blind or visually impaired for greater than 10 years, either congenitally or acquired.\n* Tactile Aid Usage: Participants must use tactile aids regularly.\n* Mathematical Knowledge: Participants should have a basic understanding of mathematical plots, equivalent to at least high school geometry.\n\nExclusion Criteria:\n\n\\- Limb Conditions: Participants with amputations or outer extremity conditions affecting hand use will be excluded.","16 Years",{"count":310,"type":21},100,[72],"The objective of this project is to create richer tactile aids by using materials chemistry to create tactile sensations in tactile aids, as an alternative to traditional physical bumps, lines, or textures. These materials are commonly used in household products, but have not yet been used to enrich tactile aids. Successful outcomes are primarily the accuracy with which low vision or blind subjects identify objects made from tactile coatings versus traditional tactile aids. Other outcomes include time to completion of the task, or the number of distinctive categories that participants can identify.",[86,28],[204],"2024-03-11",{"date":317,"type":51},"2024-03-13",{"date":319,"type":51},"2021-09-01",{"date":321,"type":21},"2027-12",{"name":213,"class":154}]